Prelude Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
Sell
-5,408
Closed -$1.46M 985
2025
Q1
$1.46M Buy
5,408
+595
+12% +$161K 0.11% 182
2024
Q4
$1.13M Sell
4,813
-20
-0.4% -$4.71K 0.07% 289
2024
Q3
$1.33M Sell
4,833
-100
-2% -$27.5K 0.08% 270
2024
Q2
$1.2M Sell
4,933
-1,998
-29% -$486K 0.08% 249
2024
Q1
$1.04M Buy
6,931
+5,275
+319% +$788K 0.05% 358
2023
Q4
$317K Buy
+1,656
New +$317K 0.02% 610
2023
Q2
Sell
-1,788
Closed -$358K 984
2023
Q1
$358K Buy
+1,788
New +$358K 0.02% 514
2021
Q4
Sell
-4,755
Closed -$898K 1585
2021
Q3
$898K Sell
4,755
-3,209
-40% -$606K 0.02% 446
2021
Q2
$1.35M Sell
7,964
-6,216
-44% -$1.05M 0.04% 347
2021
Q1
$2M Buy
+14,180
New +$2M 0.05% 176
2020
Q4
Sell
-1,230
Closed -$179K 775
2020
Q3
$179K Sell
1,230
-836
-40% -$122K 0.01% 523
2020
Q2
$306K Buy
+2,066
New +$306K 0.02% 404
2018
Q4
Hold
0
1371
2018
Q3
Hold
0
1343
2018
Q2
Hold
0
1343
2017
Q4
Hold
0
1196
2017
Q3
Hold
0
1462
2016
Q2
Sell
-947
Closed -$59K 1500
2016
Q1
$59K Sell
947
-8,020
-89% -$500K 0.01% 862
2015
Q4
$844K Buy
8,967
+1,897
+27% +$179K 0.13% 162
2015
Q3
$568K Sell
7,070
-682
-9% -$54.8K 0.08% 225
2015
Q2
$929K Sell
7,752
-370
-5% -$44.3K 0.13% 178
2015
Q1
$848K Buy
8,122
+4,855
+149% +$507K 0.12% 209
2014
Q4
$317K Buy
+3,267
New +$317K 0.05% 449
2014
Q1
Sell
-6,085
Closed -$391K 1636
2013
Q4
$391K Hold
6,085
0.06% 389
2013
Q3
$390K Sell
6,085
-16,161
-73% -$1.04M 0.06% 305
2013
Q2
$690K Buy
+22,246
New +$690K 0.15% 148